Which glioblastoma patients will respond to immunotherapy? A biomarker may hold answers

Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas—the most common and malignant of primary brain tumors—might benefit from immunotherapy. The treatment could extend survival for an estimated 20% to 30% of patients. Currently, patients with glioblastoma do not receive this life-prolonging treatment because it has not […]

Continue Reading